Výsledky vyhledávání - "MESH: Lomustine"

Analyse rétrospective de 24 glioblastomes récidivant après radiochimiothérapie concomitante et traités par nitrosourées ou par l'association irinotécan et bévacizumab. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab]

Autor: Vauleon, Elodie, Mesbah, Habiba, Gedouin, Daniel, Lecouillard, Isabelle, Louvel, Guillaume, Hamlat, Abderrahmane, Riffaud, Laurent, Carsin, Béatrice, Quillien, Véronique, Audrain, Odile, Lesimple, Thierry

Publikováno v: Bulletin du Cancer
Bulletin du Cancer, 2012, 99 (2), pp.121-6. ⟨10.1684/bdc.2011.1528⟩
Bulletin du Cancer, John Libbey Eurotext, 2012, 99 (2), pp.121-6. ⟨10.1684/bdc.2011.1528⟩

International audience; Despite progress in the initial management of glioblastoma (GB), the vast majority of patients will experience recurrence within 2-3 years. The medical treatment of these recurrences is being modified by the use of antiangioge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b62f758d962f7570da705007e28c72a1
https://www.hal.inserm.fr/inserm-00662493

Zobrazit plný text záznamu

Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2010, 28 (18), pp.3028-34. ⟨10.1200/JCO.2009.26.4648⟩
Journal of Clinical Oncology, 2010, 28 (18), pp.3028-34. ⟨10.1200/JCO.2009.26.4648⟩

Purpose No significant improvement in treatment outcome has been seen in elderly patients with acute myeloid leukemia (AML) over the past 20 years. This retrospective analysis investigated the prognostic factors for complete remission (CR) and surviv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3cb2be01556cd53fb5f7f4bed5d44a5
https://pubmed.ncbi.nlm.nih.gov/20479424

Zobrazit plný text záznamu

Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer

Autor: M. Baud, Michel Febvre, Christos Chouaid, Bernard Lebeau, Marie-Josee Masanes

Publikováno v: Lung Cancer
Lung Cancer, 2010, 67 (2), pp.188-93. ⟨10.1016/j.lungcan.2009.03.024⟩
Lung Cancer, Elsevier, 2010, 67 (2), pp.188-93. ⟨10.1016/j.lungcan.2009.03.024⟩

International audience; PURPOSE: There is no standard therapy for progressive or recurrent small cell lung cancer (SCLC). Lomustine, etoposide and cyclophosphamide oral chemotherapy were evaluated in a feasibility study of efficacy survival and toxic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bcb66911a3c8e337c6f0a58fbabd1aa
https://pubmed.ncbi.nlm.nih.gov/19394109

Zobrazit plný text záznamu

[Randomised phase II study evaluating oral combination chemotherapy (CCNU, cyclophosphamide, etoposide) and intravenous chemotherapy as second-line treatment for relapsed small cell bronchial carcinoma (Trial GFPC0501)]

Autor: Gervais, R., Le Guen, Y., Le Caer, H., Paillotin, D., Chouaid, C., Renseigné, Non

Publikováno v: Revue des Maladies Respiratoires
Revue des Maladies Respiratoires, 2007, 24 (5), pp.653-8

International audience; BACKGROUND: There is no standard second-line treatment for small cell lung cancer (SCLC). The prognosis of these patients is poor and special attention should be paid to both quality of life and economic factors. METHODS: The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::53c1d96d612c9a0d71bb11d5a93cc4b0
https://hal.sorbonne-universite.fr/hal-00597115

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání